中国生物工程杂志

［1］ 许瑞安, 陈凌,肖卫东. 分子基因药物学. 北京：北京大学出版社&北京大学医学出版社, 2009, 240. Xu R A, Chen L, Xiao W. Molecular Gene Medicine. Beijing:Peking University Press and Peking University Medical Press, 2009, 240. 
［2］ Xu R A, Sun X, Tse L Y, et al. Longterm expression of angiostatin and suppression of liver metastatic cancer. Hepatology, 2003, 37(6):14511461. 
［3］ Xu R A, Harrison P M, Chen M, et al. Cytoglobin protects against damageinduced liver fibrosis. Mol Ther, 2006, 13(6):10931100. 
［4］ During M J, Xu R A, Young D, et al. Peroral gene therapy of lactose in tolerance using an adenoassociated virus vector. Nat Med, 1998, 4: 11311136. 
［5］ During M J, Symes C W, Lawlor P A, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science, 2000, 287(5457): 14531460. 
［6］ Maguire A M, Simonelli F, Pierce E A, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis.N Engl J Med, 2008, 358(21):22402248. 
［7］ Bainbridge J W, Smith A J, Barker S S, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med, 2008, 358(21):22312239. 
［8］ Hauswirth W W, Aleman T S, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: shortterm results of a phase I trial. Hum Gene Ther, 2008, 19(10): 979990. 
［9］ Mueller C, Flotte T R.Clinical gene therapy using recombinant adenoassociated virus vectors. Gene Ther, 2008, 15, 858863. 
［10］ Jacobson S G, Acland G M, Aguirre G D, et al. Safety of recombinant adenoassociated virus type 2RPE65 vector delivered by ocular subretinal injection. Mol Ther, 2006, 13:10741084. 
［11］ Le Meur G, Stieger K, Smith A J, et al. Restoration of vision in RPE65de?cient Briard dogs using an AAV serotype 4 vector that speci?cally targets the retinal pigmented epithelium. Gene Ther,2007,14:292303. 
［12］ Roman A J, Boye S L, Aleman T S, et al. Electroretinographic analyses of Rpe65mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. Mol Vis, 2007, 13:17011710. 
［13］ Cideciyan A V, Aleman T S, Boye S L, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA, 2008, 105:1511215117. 
［14］ Manno C S, Chew A J, Hutchison S, et al. AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003, 101: 29632972. 
［15］ Manno C S, Pierce G F, Arruda V R, et al. Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat Med, 2006, 12: 342347. 
［16］ Zaiss A K, Muruve D A. Immunity to adenoassociated virus vectors in animals and humans: a continued challenge. Gene Ther, 2008, 15:808816. 
［17］ Xiao W, Narendra C, Truneh A, et al. Humoral immunity to adenoassociated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol, 2000, 74:24202425. 
［18］ Xiao W, Chirmule N, Schnell M A, et al. Route of administration determines induction of Tcellindependent humoral responses to adenoassociated virus vectors. Mol Ther, 2000,1(4): 323329. 
［19］ Daya S, Berns K I. Gene therapy using adenoassociated virus vectors. Clin Microbiol Rev, 2008, 21(4):583593. 
［20］ Zabner J, Seiler M, Walters R, et al. Adenoassociated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol, 2000, 74(8): 38523858. 
［21］ Gao G, Vandenberghe L H, Alvira M R, et al. Clades of adenoassociated viruses are widely disseminated in human tissues. J Virol, 2004, 78(12):63816388. 
［22］ Halbert C L, Allen J M, Miller A D. Adenoassociated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol, 2001, 75(14):66156624. 
［23］ Limberis M P, Wilson J M. Adenoassociated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA, 2006, 103(35):1299312998. 
［24］ Mori S, Takeuchi T, Enomoto Y, et al. Tissue distribution of cynomolgus adenoassociated viruses AAV10, AAV11, and AAVcy.7 in naturally infected monkeys. Arch Virol, 2008, 153(2): 375380. 
［25］ Schmidt M, Voutetakis A, Afione S, et al. Adenoassociated virus type 12 (AAV12): a novel AAV serotype with sialic acid and heparan sulfate proteoglycanindependent transduction activity. J. Virol, 2008, 82:13991406. 
［26］ Xu R A, Janson C G, Mastakov M, et al. Quantitative comparison of expression with adenoassociated virus (AAV2) brainspecific gene cassettes. Gene Ther, 2001, 8:13231332. 
［27］ Wang Q Z, Lv Y H, Xu R A. Dosereponse and control of adenoassociated viral vectors based prechilical and clinical gene therapy. Chinese Journal Clinical Pharmacology and Therapeutics, 2008, 13(10):11821194. 
［28］ Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther, 2002, 13:13911412v 
［29］ Lu H, Qu G, Xu R, et al. Systemic elimination of de novo capsid protein synthesis from replication competent AAV contamination. Mol Ther, 2009, (in press). 
［30］ Kaplitt M G, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet, 2007, 23; 369(9579):20972105. 
［31］ Apparailly F, Khoury M, Vervoordeldonk M J, et al. Adenoassociated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther, 2005, 16(4):426434. 
［32］ Cao L, Lin E J D, Cahill M C, et al. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med, 2009, 15:447454. 
［33］吕颖慧, 王启钊，肖卫东等.自身互补型腺相关病毒载体研究进展.生物工程学报, 2009, 25(5): 658664. Lv Y, Wang Q, Xiao W, et al. Chin J Biotech,2009, 25(5): 658664. 
［34］ Liu Y L, Wagner K, Robinson N, et al. Optimized production of hightiter recombinant adenoassociated virus in roller bottles. Biotechniques, 2003, 34:184189. 
［35］ 刁勇, 许瑞安. 细胞生物技术实验指南.北京：化学化工出版社, 2009: 306337. Diao Y, Xu R A.Protocols of Cellular and Molecular Biotechnology. Beijing:Peking Chemical Industry Press, 2009: 306337. 
［36］ Chang J, Nicolas E, Marks D, et al. miR122, a mammalian liverspecific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT1. RNA Biol, 2004, 1(2):106113. 
［37］ Wang J, Xie J, Lu H, et al. Existence of transient functional doublestranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci USA, 2007, 104(32): 1310413109. 
［38］ Nathwani A C, Gray J T, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of selfcomplementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 2007, 109(4): 1414 1421. 
［39］ Nathwani A C, Gray J T, McIntosh J, et al. Selfcomplementary adenoassociated virus vectors containing a novel liverspecific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006, 107(7): 26532661. 
［40］ Miller D G, Trobridge G D, Petek L M, et al. Largescale analysis of adenoassociated virus vector integration sites in normal human cells. J Virol, 2005, 79: 1143411442. 
［41］ Nakai H, Wu X, Fuess S, et al. Largescale molecular characterization of adenoassociated virus vector integration in mouse liver. J Virol, 2005, 79: 36063614. 
［42］ Smith R H. Adenoassociated virus integration: virus versus vector. Gene Ther, 2008, 15:817822. 
［43］ Wang Q Z, Lv Y H, Yong D, et al. The design of vectors for RNAi delivery system. Curr Pharm Design, 2008, 14(13):13271340. 
［44］ Shu J B, Diao Y, Xiao W, et al. The development trend of chimeric vector of adenovirus/adeno associated viral. J Huaqiao University (Natural Science), 2008, 29(2):172176. 
［45］ Corte′s M L, Oehmig A, Saydam O, et al. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Mol Ther, 2008, 16: 8188.